联系方式：xubo851@163.com

徐波，理学博士，徐州医科大学教授，博士生导师，万人计划青年拔尖人才，江苏省特聘教授，江苏特聘医学专家，江苏卫生创新团队带头人。本硕博均毕业于中山大学。2014至2019年先后在美国俄亥俄州立大学和希望之城医学研究中心完成博士后训练，2019至2020年任美国希望之城医学研究中心研究员，2021年回国任教。课题组致力于以溶瘤病毒为主的肿瘤生物疗法研究。主持国家重点研发计划分课题1项，国地联合协同创新中心分课题1项，国家自然科学基金面上项目1项。近5年在Nature Biotechnology、Nature Cancer、Nature Communications、Clinical Cancer Research等杂志发表高水平论文10篇，平均影响因子18.60分。获美国及中国发明专利授权2项。

代表论文：

1.Bo Xu^#, Rui Ma^#, Luke Russell, Ji Young Yoo, Jianfeng Han, Hanwei Cui, Ping Yi, Jianying Zhang, Hiroshi Nakashima, Hongsheng Dai, E. Antonio Chiocca, Balveen Kaur, Michael A Caligiuri, Jianhua Yu. An oncolytic herpesvirus expressing E-cadherin improves survival in mouse models of glioblastoma.Nature Biotechnology. 2018 Nov 26: 10.1038/nbt.4302.(IF 68.164)

2.Bo Xu^#, Lei Tian^#, Jing Chen^#, Rui Ma, Wenjuan Dong, Aimin Li, Jianying Zhang, E. Antonio Chiocca, Balveen Kaur, Mingye Feng, Michael A Caligiuri, Jianhua Yu. An oncolytic virus expressing a full-length anti-CD47 antibody enhances antitumor innate immune response to glioblastoma.Nature Communications.2021 Oct 8;12(1):5908.(IF 17.69)

3.Tian L#,Xu B#, Chen Y, Li Z, Wang J, Zhang J, Ma R, Cao S, Hu W, Chiocca EA, Kaur B, Caligiuri MA*, Yu J*.Specific targeting of glioblastoma with an oncolytic virus expressing a cetuximab-CCL5 fusion protein via innate and adaptive immunity.Nature Cancer. 2022 Nov;3(11):1318-1335. (IF 23.177)

4.Tian L#,Xu B#, Teng KY, Song M, Zhu Z, Chen Y, Wang J, Zhang J, Feng M, Kaur B, Rodriguez L, Caligiuri MA*, Yu J*. Targeting Fc Receptor-Mediated Effects and the "Don't Eat Me" Signal with an Oncolytic Virus Expressing an Anti-CD47 Antibody to Treat Metastatic Ovarian Cancer.Clin Cancer Res. 2022 Jan 1;28(1):201-214. (IF 13.8)

5.Xu Bu^#, Wang L^#, González-Molleda L^#, Wang Y, Xu J, Yuan Y. Antiviral activity of (+)-rutamarin against Kaposi's sarcoma-associated herpesvirus by inhibition of the catalytic activity of human topoisomerase II.Antimicrob Agents Chemother. 2014 Jan;58(1):563-73.

6.Hui Cui^#,BoXu^#, Taizong Wu, Jun Xu, Yan Yuan, Qiong Gu. Potential antiviral lignans from the roots of Saururus chinensis with activity against Epstein-Barr virus lytic replication.J Nat Prod. 2014 Jan 24;77(1):100-10.

7.Jun 7;2021.06.07.447286..doi: 10.1101/2021.06.07.447286. Preprint.

8.Xu Cao, Bolei Li, Jing Chen, Jessica Dang, Siqi Chen, E Gulsen Gunes,Bo Xu, Lei Tian, Sabina Muend, Mustafa Raoof, Christiane Querfeld, Jianhua Yu, Steven T Rosen, Yingyu Wang, Mingye Feng.Effect of cabazitaxel on macrophages improves CD47-targeted immunotherapy for triple-negative breast cancer.J Immunother Cancer.2021 Mar;9(3):e002022. doi: 10.1136/jitc-2020-002022.

9.Manchao Zhang, Scarlett Acklin, John Gillenwater, Wuying Du, Mousumi Patra, Hao Yu,Bo Xu, Jianhua Yu, Fen Xia.SIRT2 promotes murine melanoma progression through natural killer cell inhibition.Scientific Reports.2021 Jun 21;11(1):12988.

10.Rui Ma, Ting Lu, Zhenlong Li, Kun-Yu Teng, Anthony G Mansour, Melissa Yu, Lei Tian,Bo Xu, Shoubao Ma, Jianying Zhang, Tasha Barr, Yong Peng, Michael A Caligiuri, Jianhua Yu.An oncolytic virus expressing IL-15/IL-15Rα combined with off-the-shelf EGFR-CAR NK cells targets glioblastoma.Cancer Research. 2021 May 18;canres.0035.2021. doi: 10.1158/0008-5472.CAN-21-0035.

11.Xinxin Li, Wenjuan Dong, Ansel P Nalin, Yufeng Wang, Pan Pan,Bo Xu, Yibo Zhang, Steven Tun, Jianying Zhang, Li-Shu Wang, Xiaoming He, Michael A Caligiuri, Jianhua Yu. The natural product chitosan enhances the anti-tumor activity of natural killer cells by activating dendritic cells.Oncoimmunology. 2018 Mar 13;7(6):e1431085.

12.Chelsea Bolyar, W Hans Meisen, Yeshavanth Banasavadi-Siddegowda, Jayson Hardcastle, Ji Young Yoo, Eric S Wohleb, Jeffrey Wojton, Jun-Ge Yu, Samuel Dubin, Maninder Khosla,Bo Xu, Jonathan Smith, Christopher Alvarez-Breckenridge, Pete Pow-Anpongkul, Flavia Pichiorri, Jianying Zhang, Matthew Old, Dan Zhu, Erwin G Van Meir, Jonathan P Godbout, Michael A Caligiuri, Jianhua Yu, Balveen Kaur. BAI1 Orchestrates Macrophage Inflammatory Response to HSV Infection-Implications for Oncolytic Viral Therapy.Clin Cancer Res. 2017 Apr 1;23(7):1809-1819. doi: 10.1158/1078-0432.CCR-16-1818. Epub 2016 Nov 9.

13.Jianfeng Han, Xilin Chen, Jianhong Chu,Bo Xu, Walter H Meisen, Lichao Chen, Lingling Zhang, Jianying Zhang, Xiaoming He, Qi-En Wang, E Antonio Chiocca, Balveen Kaur, Michael A Caligiuri, Jianhua Yu. TGFβ Treatment Enhances Glioblastoma Virotherapy by Inhibiting the Innate Immune Response.Cancer Res. 2015 Dec 15;75(24):5273-82. doi: 10.1158/0008-5472.CAN-15-0894. Epub 2015 Dec 2.

研究方向

近年来，溶瘤病毒作为一种新兴的肿瘤生物治疗方法取得了多项突破性研究进展。溶瘤病毒T-VEC和G47Δ相继在美国和日本获批上市，凸显了溶瘤病毒的临床应用前景和市场价值。

然而，溶瘤病毒在实际临床应用中仍面临诸多困难和挑战。1）溶瘤病毒强大的免疫原性虽有助于激活免疫反应发挥抗肿瘤所用，但也导致溶瘤病毒极易被免疫清除，致使瘤病毒作用持续时间严重受限；2）实体肿瘤内致密的组织结构和细胞间质等均不利于溶瘤病毒感染扩散；3）肿瘤的免疫逃逸特性导致溶瘤病毒激活的免疫反应无法充分发挥抗肿瘤所用；4）现有溶瘤病毒普遍采用瘤内给药，难以采用静脉注射等系统给药方式。

为此，我们将利用病毒重组技术、生物化学、细胞生物学和生物信息学等手段，针对以上限制溶瘤病毒临床疗效的关键难题展开深入系统的研究。主要开展以下四个方面的研究工作：

1.研究溶瘤病毒与免疫反应的相互作用，重点关注NK细胞、巨噬细胞和中和抗体在清除病毒感染中的作用，分阶段精准调控免疫反应以提高溶瘤病毒作用持续时间；

2.开发可靶向诱导肿瘤细胞融合的溶瘤病毒，利用细胞融合提高溶瘤病毒在肿瘤内的感染扩散。

3.开展溶瘤病毒与免疫细胞疗法的协同抗肿瘤治疗研究，针对免疫细胞疗法抗实体瘤的难题，通过溶瘤病毒递送肿瘤抗原、免疫调控因子等提高抗肿瘤疗效。

4.开发肿瘤感染靶向型溶瘤病毒，并利用生物活性材料作为递送载体，开发可通过静脉给药的溶瘤病毒疗法。